Effect of atrial natriuretic peptide on DOPA potentiation in mice

Amelia Bidzseranova, Jony Gueron, G. Tóth, B. Penke, G. Telegdy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The effect of rat atrial natriuretic peptide (ANP1-28) on the pargyline-DOPA potentiation test was studied following its administration into the lateral brain ventricle in mice. Thirty minutes after pargyline pretreatment, three doses of ANP (200, 500, or 1,000 ng/mouse) were administered simultaneously with DOPA and animals were then observed for 2 h. ANP in doses of 500 and 1,000 ng markedly enhanced the effect of DOPA. The maximum intensity of the effect was registered 30-45 min following administration of the peptide. The data suggest that ANP might be regarded as a dopaminergic-modulating agent in the CNS.

Original languageEnglish
Pages (from-to)767-768
Number of pages2
JournalBrain Research Bulletin
Volume28
Issue number5
DOIs
Publication statusPublished - 1992

Fingerprint

Atrial Natriuretic Factor
Pargyline
Dopamine Agents
Lateral Ventricles
Peptides
Brain

Keywords

  • Atrial natriuretic peptide
  • DOPA potentiation
  • Pargyline

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Effect of atrial natriuretic peptide on DOPA potentiation in mice. / Bidzseranova, Amelia; Gueron, Jony; Tóth, G.; Penke, B.; Telegdy, G.

In: Brain Research Bulletin, Vol. 28, No. 5, 1992, p. 767-768.

Research output: Contribution to journalArticle

@article{e2e7308194a4411a893f4716d66b9459,
title = "Effect of atrial natriuretic peptide on DOPA potentiation in mice",
abstract = "The effect of rat atrial natriuretic peptide (ANP1-28) on the pargyline-DOPA potentiation test was studied following its administration into the lateral brain ventricle in mice. Thirty minutes after pargyline pretreatment, three doses of ANP (200, 500, or 1,000 ng/mouse) were administered simultaneously with DOPA and animals were then observed for 2 h. ANP in doses of 500 and 1,000 ng markedly enhanced the effect of DOPA. The maximum intensity of the effect was registered 30-45 min following administration of the peptide. The data suggest that ANP might be regarded as a dopaminergic-modulating agent in the CNS.",
keywords = "Atrial natriuretic peptide, DOPA potentiation, Pargyline",
author = "Amelia Bidzseranova and Jony Gueron and G. T{\'o}th and B. Penke and G. Telegdy",
year = "1992",
doi = "10.1016/0361-9230(92)90257-X",
language = "English",
volume = "28",
pages = "767--768",
journal = "Brain Research Bulletin",
issn = "0361-9230",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Effect of atrial natriuretic peptide on DOPA potentiation in mice

AU - Bidzseranova, Amelia

AU - Gueron, Jony

AU - Tóth, G.

AU - Penke, B.

AU - Telegdy, G.

PY - 1992

Y1 - 1992

N2 - The effect of rat atrial natriuretic peptide (ANP1-28) on the pargyline-DOPA potentiation test was studied following its administration into the lateral brain ventricle in mice. Thirty minutes after pargyline pretreatment, three doses of ANP (200, 500, or 1,000 ng/mouse) were administered simultaneously with DOPA and animals were then observed for 2 h. ANP in doses of 500 and 1,000 ng markedly enhanced the effect of DOPA. The maximum intensity of the effect was registered 30-45 min following administration of the peptide. The data suggest that ANP might be regarded as a dopaminergic-modulating agent in the CNS.

AB - The effect of rat atrial natriuretic peptide (ANP1-28) on the pargyline-DOPA potentiation test was studied following its administration into the lateral brain ventricle in mice. Thirty minutes after pargyline pretreatment, three doses of ANP (200, 500, or 1,000 ng/mouse) were administered simultaneously with DOPA and animals were then observed for 2 h. ANP in doses of 500 and 1,000 ng markedly enhanced the effect of DOPA. The maximum intensity of the effect was registered 30-45 min following administration of the peptide. The data suggest that ANP might be regarded as a dopaminergic-modulating agent in the CNS.

KW - Atrial natriuretic peptide

KW - DOPA potentiation

KW - Pargyline

UR - http://www.scopus.com/inward/record.url?scp=0026629388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026629388&partnerID=8YFLogxK

U2 - 10.1016/0361-9230(92)90257-X

DO - 10.1016/0361-9230(92)90257-X

M3 - Article

VL - 28

SP - 767

EP - 768

JO - Brain Research Bulletin

JF - Brain Research Bulletin

SN - 0361-9230

IS - 5

ER -